PET for neurofibromatosis – pro
Malignant peripheral nerve sheath tumours (MPNSTs) are difficult to diagnose and treat and contribute to significant morbidity and mortality for patients with Neurofibromatosis-1 (NF-1). FDG-PET/CT is being increasingly used as an imaging modality to discriminate between benign and malignant plexiform neurofibromas.There is singificnat literature, although nto yet guideliens, supproting the role of PET to make this eifferentiation. The systematic review bu Tpvmassian et al asuggested that FDG-PET/CT is a useful noninvasive test for discriminating between benign and malignant lesions but also stated that it has limitations and requires further prospective trials. There are also reports, but not prospective trials, suggesting that PET can be used to discover the systemic lesions and to discriminate between benign and malignant plexiform neurofibromas.
This is a flat rate case as you have previously accepted.
Tovmassian D, Abdul Razak M, London K. The Role of [18F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1. Int J Surg Oncol. 2016;2016:6162182.
Puranik AD, Purandare NC, Bal MM, Agrawal A, Shah S, Rangarajan V. FDG PET/CT detects benign neurofibromas presenting as nodal masses: Imaging hallmarks of a diagnostic “red herring”. Indian J Nucl Med. 2015;30(2):148-50.
Ren J, Yang G, Zhou J, Fu Z. The value of 18F-FDG PET/CT in patient with neurofibromatosis type 1: A case report and literature review. Medicine (Baltimore). 2018;97(20):e10648.